Sadia Zafar

Sadia Zafar

Auto-generated profile, based on publicly available information

Sadia Zafar

Applied Tumor Genomics Faculty of Medicine Research Programs Unit University of Helsinki Helsinki Finland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2024 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
LMLeo Meriranta
Leo Meriranta
SSSelma Sorri
Selma Sorri
KHKanutte Huse
Kanutte Huse
XLXiaonan Liu
Xiaonan Liu
ISIvana Spasevska
Ivana Spasevska
SLSirpa Leppä
Sirpa Leppä
Pathomechanisms that activate oncogenic B-cell receptor (BCR) signaling in diffuse large B-cell lymphoma (DLBCL) are largely unknown. Kelch-like family member 6 (KLHL6) encoding a substrate-adapter for Cullin-3-RING E3 ubiquitin ligase with poorly established targets is recurrently mutated in DLBCL. By applying high-throughput protein interactome screens and functional characterization, we discovered that KLHL6 regulates BCR by targeting its signaling subunits CD79A and CD79B. Loss of physiologic KLHL6 expression pattern was frequent among the MCD/C5-like activated B-cell DLBCLs and was associated with higher CD79B levels and dismal outcome. Mutations in the bric-a-brac tramtrack broad domain of KLHL6 disrupted its localization and heterodimerization and increased surface BCR levels and signaling, whereas Kelch domain mutants had the opposite effect. Malfunctions of KLHL6 mutants extended beyond proximal BCR signaling with distinct phenotypes from KLHL6 silencing. Collectively, our findings uncover how recurrent mutations in KLHL6 alter BCR signaling and induce actionable phenotypic characteristics in DLBCL. Significance: Oncogenic BCR signaling sustains DLBCL cells. We discovered that Cullin-3-RING E3 ubiquitin ligase substrate-adapter KLHL6 targets BCR heterodimer (CD79A/CD79B) for ubiquitin-mediated degradation. Recurrent somatic mutations in the KLHL6 gene cause corrupt BCR signaling by disrupting surface BCR homeostasis. Loss of KLHL6 expression and mutant-induced phenotypes associate with targetable disease characteristics in B-cell lymphoma. See related commentary by Leveille et al. See related commentary by Corcoran et al.

6 February 2024 in International Journal of Cancer
Verified
Journal Article
Open access
PNPirjo Nummela
Pirjo Nummela
SZSadia Zafar
Sadia Zafar
EVErika Veikkolainen
Erika Veikkolainen
IUIiris Ukkola
Iiris Ukkola
VCVincenzo Cinella
Vincenzo Cinella
ARAri Ristimäki
Ari Ristimäki
Approximately 5% of colorectal cancers (CRCs) have a gain‐of‐function mutation in the GNAS gene, which leads to the activation of cAMP‐dependent signaling pathways and associates with poor prognosis. We investigated the effect of an activating GNAS mutation in CRC cell lines on gene expression and cell proliferation in vitro, and tumor growth in vivo. GNAS‐mutated (GNASmt) HCT116 cells showed stimulated synthesis of cAMP as compared to parental (Par) cells. The most upregulated gene in the GNASmt cells was cAMP‐hydrolyzing phosphodiesterase 4D (PDE4D) as detected by RNA sequencing. To further validate our finding, we analyzed PDE4D expression in a set of human CRC tumors (n = 35) and demonstrated overexpression in GNAS mutant CRC tumors as compared to GNAS wild‐type tumors. The GNASmt HCT116 cells proliferated more slowly than the Par cells. PDE4 inhibitor Ro 20‐1724 and PDE4D subtype selective inhibitor GEBR‐7b further suppressed the proliferation of GNASmt cells without an effect on Par cells. The growth inhibitory effect of these inhibitors was also seen in the intrinsically GNAS‐mutated SK‐CO‐1 CRC cell line having high levels of cAMP synthesis and PDE4D expression. In vivo, GNASmt HCT116 cells formed smaller tumors than the Par cells in nude mice. In conclusion, our findings demonstrate that GNAS mutation results in the growth suppression of CRC cells. Moreover, the GNAS mutation‐induced overexpression of PDE4D provides a potential avenue to impede the proliferation of CRC cells through the use of PDE4 inhibitors.

3 September 2024
Verified
Other
Open access
LMLeo Meriranta
Leo Meriranta
SSSelma Sorri
Selma Sorri
KHKanutte Huse
Kanutte Huse
XLXiaonan Liu
Xiaonan Liu
ISIvana Spasevska
Ivana Spasevska
SLSirpa Leppä
Sirpa Leppä
Recurrent KLHL6 mutations extend their pathogenic malfunctions to BANK1 and LuZP1. A, Representative IF microscopy images of SuDHL4 cells transduced with select KLHL6 constructs immunostained for endogenous BANK1, KLHL6, and DNA (Hoechst). WT overexpression; Scale bar, 10 µm. B, BANK1-KLHL6 colocalization for different KLHL6 overexpression constructs in SuDHL4 cells measured from fluorescent microscopy images. Staining from endogenous KLHL6 (ED) from the nontransduced parental cell line used as a control. Each point represents the correlation coefficient of one analyzed image. P value calculated with the Kruskal–Wallis test. MCC, Manders’ correlation coefficient. C, Spectral counts of BANK1 peptides from different affinity-purified in SuDHL5 pull-downs according to WT and mutant Strep-tagged baits. Dots represent biological pull-down replicates. D, Western blot analyses of BANK1 in SuDHL4, SuDHL5, and U2932 cell lines transduced with EmGFP control and nontagged KLHL6 WT and mutant constructs. Quantification of the signal intensity was normalized to a housekeeping control (β-actin) and compared with signal from EmGFP transduced cells. E, PCA of mass spectrometry data from SuDHL5 cells transduced with different BioID2-tagged constructs. F and G, Volcano plots of differentially interacting proteins between WT and Kelch mutant (E547K and E568K) BioID2-tagged KLHL6 baits. H, Spectral counts of LuZP1 in BioID2 interactome screens from SuDHL5 cells transduced with the appropriate constructs. Controls include in-house purifications with various unrelated BioID2 purifications from SuDHL5 cells to demonstrate the level of background noise for LuZP1 prey. Mann–Whitney U test. P value for comparison between WT and KLHL6L65P counts is shown. I and J, Representative IF images showing colocalization between endogenous KLHL6 and centrosomal LuZP1 proteins in unmanipulated lymphoma cell lines. Arrowheads point LuZP1 signal per representative cell. Scale bar, 20 µm. K, Western blot analysis of cell lysates from SuDHL5 cells transduced with KLHL6 WT and mutant constructs or EmGFP control. L, Balloon plot of SAINT analysis of interactome screening with BioID2-tagged KLHL6 baits. Size of the balloons represents SAINT score with high-confidence interactions (≥0.95) annotated with red borders. Fold-change of spectral counts represented with color fill. M, Representative IF images of SuDHL5 cells overexpressing KLHL6L65P mutant stained for KLHL6 and SEC16A. Red arrowheads indicate co-staining vesicles. Scale bar, 10 µm.

3 September 2024
Verified
Other
Open access
LMLeo Meriranta
Leo Meriranta
SSSelma Sorri
Selma Sorri
KHKanutte Huse
Kanutte Huse
XLXiaonan Liu
Xiaonan Liu
ISIvana Spasevska
Ivana Spasevska
SLSirpa Leppä
Sirpa Leppä
Pathomechanisms that activate oncogenic B-cell receptor (BCR) signaling in diffuse large B-cell lymphoma (DLBCL) are largely unknown. Kelch-like family member 6 (KLHL6) encoding a substrate-adapter for Cullin-3-RING E3 ubiquitin ligase with poorly established targets is recurrently mutated in DLBCL. By applying high-throughput protein interactome screens and functional characterization, we discovered that KLHL6 regulates BCR by targeting its signaling subunits CD79A and CD79B. Loss of physiologic KLHL6 expression pattern was frequent among the MCD/C5-like activated B-cell DLBCLs and was associated with higher CD79B levels and dismal outcome. Mutations in the bric-a-brac tramtrack broad domain of KLHL6 disrupted its localization and heterodimerization and increased surface BCR levels and signaling, whereas Kelch domain mutants had the opposite effect. Malfunctions of KLHL6 mutants extended beyond proximal BCR signaling with distinct phenotypes from KLHL6 silencing. Collectively, our findings uncover how recurrent mutations in KLHL6 alter BCR signaling and induce actionable phenotypic characteristics in DLBCL.Significance: Oncogenic BCR signaling sustains DLBCL cells. We discovered that Cullin-3-RING E3 ubiquitin ligase substrate-adapter KLHL6 targets BCR heterodimer (CD79A/CD79B) for ubiquitin-mediated degradation. Recurrent somatic mutations in the KLHL6 gene cause corrupt BCR signaling by disrupting surface BCR homeostasis. Loss of KLHL6 expression and mutant-induced phenotypes associate with targetable disease characteristics in B-cell lymphoma.See related commentary by Leveille et al.See related commentary by Corcoran et al.

3 September 2024
Verified
Other
Open access
LMLeo Meriranta
Leo Meriranta
SSSelma Sorri
Selma Sorri
KHKanutte Huse
Kanutte Huse
XLXiaonan Liu
Xiaonan Liu
ISIvana Spasevska
Ivana Spasevska
SLSirpa Leppä
Sirpa Leppä
Table S2 shows recurrent KLHL6 mutations reported in DLBCL.

3 September 2024
Verified
Other
Open access
PDF file
LMLeo Meriranta
Leo Meriranta
SSSelma Sorri
Selma Sorri
KHKanutte Huse
Kanutte Huse
XLXiaonan Liu
Xiaonan Liu
ISIvana Spasevska
Ivana Spasevska
SLSirpa Leppä
Sirpa Leppä
Figure S1 shows KLHL6 expression and its molecular correlates in reactive lymphoid and DLBCL tissues. Figure S2 shows recurrent KLHL6 mutations and their subcellular localization. Figure S3 shows data from affinity-purification mass-spectrometry (AP-MS) interactome analysis of Strep-tagged wild-type KLHL6 in the expansion cell line panel. Figure S4 shows data related to proximity-labeling interactome analysis of KLHL6. Figure S5 shows KLHL6 interactome upon BCR stimulation and the impact of recurrent mutations on BCR levels. Figure S6 shows the impact of KLHL6 constructs on the surface levels expression of the BCR components. Figure S7 shows the impact of KLHL6 constructs on the BCR signaling. Figure S8 shows immunofluorescent analysis and quantification of CD79B staining intensity. Figure S9 shows BANK1 expression in DLBCL.